serelaxin
Recombinant proteinexperimental
Serelaxin is a medication which is marketed in Russia for the treatment of acute heart failure (AHF), targeting the relaxin receptor. It was also under development in other places in the world, including in the United States, Europe, and Asia, but ultimately was not marketed in these areas. — Wikipedia
Clinical trial activity
16 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
14
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00259103)
Timeline
Indications
Mechanism of action
- Relaxin receptor 1ACTIVATOR
RXFP1 activator
Peptide, recombinant human relaxin-2. EMA and FDA regulators have rejected marketing authorisation.
- Relaxin receptor 2ACTIVATOR
RXFP2 activator
Peptide, recombinant human relaxin-2. EMA and FDA regulators have rejected marketing authorisation.
- Prorelaxin H1Supplementation
RLN1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSerelaxin ↗
- ChEMBLCHEMBL2108358 ↗
Also known as
- human relaxin 2 (relaxin h2)
- human relaxin 2 (relaxin h2)
- human relaxin recombinant
- recombinant human relaxin
- rlx030
- rlx030
- serelaxin
- serelaxin
- serelaxin
- serelaxin
- serelaxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02669875 | Phase 2 | May 31, 2017 | NHS Lothian, Novartis, University of Edinburgh |
| NCT02625922 | Phase 2 | Feb 5, 2016 | Novartis |
| NCT02151383 | Phase 2 | Sep 5, 2014 | Novartis |
| NCT01982292 | Phase 2 | May 1, 2014 | Novartis |
| NCT02007720 | Phase 3 | Mar 12, 2014 | Novartis |
| NCT01979614 | Phase 2 | Feb 1, 2014 | Novartis |
| NCT02064868 | Phase 3 | Jan 31, 2014 | Novartis |
| NCT02002702 | Phase 2 | Jan 1, 2014 | Novartis |
| NCT01870778 | Phase 3 | Oct 1, 2013 | Novartis |
| NCT01875523 | Phase 1 | Aug 1, 2013 | Novartis |
| NCT01566630 | Phase 2 | May 1, 2013 | Novartis |
| NCT01640964 | Phase 2 | Apr 1, 2013 | Novartis |
| NCT01543854 | Phase 2 | Mar 1, 2012 | Novartis |
| NCT01546532 | Phase 2 | Feb 1, 2012 | Novartis |
| NCT01433458 | Phase 1 | Jul 1, 2011 | Novartis |
| NCT00259103 | Phase 2 | Nov 1, 2005 | BAS Medical, Inc., Corthera |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 15 | 14 | 3 | 2011 |
| BAS Medical, Inc. | For profit | 1 | 0 | 1 | 2005 |
| Corthera | For profit | 1 | 1 | 1 | 2005 |
| NHS Lothian | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Edinburgh | Academic/Hospital | 1 | 1 | 1 | 2017 |
5 organizations
Page 1 / 1